CN1221268C - 镁钙离子复合制剂及其生产工艺 - Google Patents
镁钙离子复合制剂及其生产工艺 Download PDFInfo
- Publication number
- CN1221268C CN1221268C CN 02130855 CN02130855A CN1221268C CN 1221268 C CN1221268 C CN 1221268C CN 02130855 CN02130855 CN 02130855 CN 02130855 A CN02130855 A CN 02130855A CN 1221268 C CN1221268 C CN 1221268C
- Authority
- CN
- China
- Prior art keywords
- magnesium
- calcium
- calcium ion
- acetate
- gram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229910001424 calcium ion Inorganic materials 0.000 title claims abstract description 22
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 239000002131 composite material Substances 0.000 title abstract 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000011777 magnesium Substances 0.000 claims abstract description 26
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 25
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 22
- 239000000243 solution Substances 0.000 claims abstract description 21
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 13
- 238000005516 engineering process Methods 0.000 claims abstract description 13
- 239000008101 lactose Substances 0.000 claims abstract description 13
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims abstract description 12
- 239000001639 calcium acetate Substances 0.000 claims abstract description 12
- 235000011092 calcium acetate Nutrition 0.000 claims abstract description 12
- 229960005147 calcium acetate Drugs 0.000 claims abstract description 12
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims abstract description 12
- 239000011654 magnesium acetate Substances 0.000 claims abstract description 12
- 235000011285 magnesium acetate Nutrition 0.000 claims abstract description 12
- 229940069446 magnesium acetate Drugs 0.000 claims abstract description 12
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 11
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 10
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 10
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000011259 mixed solution Substances 0.000 claims abstract description 5
- 229960000583 acetic acid Drugs 0.000 claims description 14
- 239000012362 glacial acetic acid Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 9
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 229940013618 stevioside Drugs 0.000 claims description 7
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 7
- 235000019202 steviosides Nutrition 0.000 claims description 7
- 238000010792 warming Methods 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- 229960001375 lactose Drugs 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 24
- 239000011575 calcium Substances 0.000 abstract description 24
- 229910052791 calcium Inorganic materials 0.000 abstract description 24
- 229910001425 magnesium ion Inorganic materials 0.000 abstract description 6
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 abstract description 5
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 208000001132 Osteoporosis Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 208000015606 cardiovascular system disease Diseases 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract 1
- 229940091250 magnesium supplement Drugs 0.000 description 25
- 229960005069 calcium Drugs 0.000 description 23
- 229910052500 inorganic mineral Inorganic materials 0.000 description 14
- 235000010755 mineral Nutrition 0.000 description 14
- 239000011707 mineral Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 235000011001 calcium citrates Nutrition 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 108010090279 galactose permease Proteins 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960002203 tilactase Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及一种镁钙离子复合制剂及其生产工艺,其特点是它是用冰醋酸分别与氧化镁和碳酸钙进行化学反应,生成醋酸镁和醋酸钙溶液,将两者混合后,加入适量的乳糖及其它辅助原料而成,每10毫升混合溶液中含镁离子70毫克,钙离子200毫克,镁、钙离子含量比为1∶2-4,产品主要用于特殊营养素补充剂,适用于镁、钙缺乏人群,主要是心血管系统疾病和骨质疏松病人,可以用于此类疾病的预防和辅助治疗。
Description
技术领域
本发明涉及一种补充人体所需的镁钙常量元素而研制的膳食补充品-镁钙离子复合制剂及其生产工艺。
背景技术
矿物质与身体组织有关,也与各种系统的功能有关,如血液和骨骼的形成,神经的功能,肌肉的调节。矿物质可作为辅酶参与物质的代谢,能量的生产,维生素及其它营养素的利用。人体必须维持正常的化学平衡,这种平衡要依靠体内矿物质的比例。如果一种矿物质的比例失调,便会影响所有的矿物质产生链式反应,以致化学反应失去平衡,而导致疾病。目前,在发达国家将矿物质与维生素合在一起做成片剂,作为保健食品或者膳食补品。一般矿物质是与蛋白质以螯合的形式组成的,这样使矿物质容易吸收并在血液中转运。在进食时服用矿物质,消化过程中矿物质在胃中形成螯合物而被吸收。矿物质的服用量不能过大,其重要原因是吸收时,它们是相互竞争的,如果某一矿物质过多,便会挤掉另外的矿物质而使其它的矿物质发生缺乏。钙是人体食量较多的元素之一,在人体中的含量仅次于氢、氧、碳、氮而居于第五位,钙在人体的总量约为1300g,约占体重的1.5-0.75%,其中99%的钙存在于骨骼,骨骼是人体的重要支柱。骨骼之外的钙虽然只占1%,但它却在体内起重要作用,钙存在于细包外液,软组织,并为细胞膜的成分之一。钙参与凝血过程,对肌肉的收缩,包括心肌的正常作用以及神经肌肉的应激有重要作用。若离子钙在血浆中明显下降,则神经肌肉的应激性就会大大增加,以致于手足抽搐。相反,若钙离子在血中过高,则可引起心脏与呼吸的衰竭。镁对人体许多功能的发挥都有关,镁在维持身体整体健康的平衡方面发挥着极其微妙的作用。镁最大的作用是对细胞内流通的钙进行调节。正是这种微妙协调决定着人体细胞火焰的频率。镁与钙在生产三磷酸腺苷(ATP)的过程中结成了特殊伙伴关系。ATP酶是我们从事任何活动的动力源泉,它寄存在活细胞内部,镁把守着这些细胞大门,而钙只有进入里面才能产生足够的ATP。镁对人体中的300多种酶都起到激活作用,人体所有的蛋白质合成过程都需要镁参与。核酸的水解,吸收和利用过程必须有镁的参与。镁不仅影响血中的葡萄糖转换,还影响脂肪及能量代谢。现在将碳酸钙和氧化镁分别直接压成片剂,或者合成压成片剂在国外很普遍。由于钙镁均为二价的阳高子,服用后需要依赖胃酸溶解,100毫克的碳酸钙完全溶解需要230毫升的胃酸,对老年人来说每天不到1000毫升的胃酸负担似乎过重。如果将钙、镁分别服用,还存在着服用量比例不易掌握的问题,钙、镁离子相互之间的竞争吸收,相互干挠,影响了吸收率。
发明内容
本发明的目的就是研制出一种按人体胃肠吸收的最佳浓度配比,以液态物质作为钙、镁离子载体的镁钙离子复合制剂及其生产工艺。
本发明所述的镁钙离子复合制剂生产工艺方案如下:
按生产1000毫升的镁钙复合制剂需用配料计算用料,需:
冰醋酸 124-138毫升
碳酸钙 51-57克
氧化镁 11-12克
乳 糖 9.5-10.5克
甜菊糖苷 6-7克
其余为去离子水
生产工艺:
用醋酸分别与氧化镁和碳酸钙进行化学反应,生成醋酸镁溶液和醋酸钙溶液,将醋酸钙溶液和醋酸镁溶液进行混合,形成混合液。向溶液中加入适量的乳糖及其它辅助原料。使溶液达到规定的浓度:每10毫升混合液中,含镁离子70毫克,钙离子200毫克。
生产中加入冰醋酸的作用是用醋酸溶解碳酸钙形成醋酸钙溶液,醋酸与氧化镁反应生成醋酸镁溶液,在醋酸镁和醋酸钙溶液中,镁、钙呈2价离子态存在,也就是说呈胃酸溶解后的状态存在。老年人胃酸分泌及胃蛋白酶合成减少,对镁、钙不能充分溶解吸收,而本产品元素全部呈液体离子状态,易被肠道直接吸收,醋酸根对人体的作用不仅是利于多种氨基酸合成,还能扩张血管增强微循环。本产品加入一定量的乳糖,用乳糖来促进钙、镁的吸收。乳糖只在乳汁中存在,是母体供给婴儿最重要的营养物质。乳糖进入人体后,迅速分解为半乳糖,形成半乳糖苷酶,半乳糖透性酶等,不仅促进镁的吸收,还能增强镁对酶的活化作用。本产品镁与钙离子的浓度比更符合中国人的饮食及生理特征。医学研究发现,肠道中镁、钙离子浓度比为1∶2时,吸收率较高。国外进口的镁钙制剂,镁钙含量比通常按1∶2设计。但是,中国人饮食中钙含量偏低,多数人服用进口的钙镁制剂,钙、镁浓度比不能达到1∶2的状态,本产品增加了钙的含量,使镁、钙浓度比达到1∶2-4,多数人服用后,肠道内的镁、钙浓度比更接近1∶2的状态。本产品解决了老年人健康的主要矛盾,心脑血管疾病,糖尿病及骨质疏松症。每10毫升的本产品口服液,含钙离子200毫克,相当于碳酸钙500毫克,果(糖)酸钙1532毫克,葡萄糖酸钙2237毫克,柠檬酸钙2853毫克,是补镁和钙的特殊营养素补充剂,适用于镁钙缺乏人群,主要是心血管系统疾病和骨质疏松病人,可以用于此类病症的预防和辅助治疗。
附图说明
本发明工艺流程图
具体实施方式
实施例1
取64毫升冰醋酸,将其稀释成10%浓度的冰醋酸,然后投入反应器中,升温至50℃,取54克碳酸钙粉,缓慢加入并搅拌继续升温至75℃,恒温35分钟继续反应。另取67毫升的冰醋酸,将其稀释成10%浓度的冰醋酸,投入反应器中,升温至50℃,取11.5克氧化镁,缓慢加入反应器并搅拌,继续升温至70℃,恒温25分钟继续反应。将上述两种反应生成物醋酸钙溶液和醋酸镁溶液放入同一容器中混合,在混合后的溶液中加入6.5克的甜菊糖苷,10克乳糖。将配制液升温至90℃,并恒温至45分钟,使其充分完成反应。自然冷却至常温。将溶液用过滤器过滤。将去离子水加入经过过滤的配制液,至配制量1000毫升。然后分装于玻璃瓶中,流通蒸汽100℃灭菌30分钟。得到的产品,镁、钙离子浓度比为1∶2.86。
实施例2
分别取61毫升和63毫升冰醋酸,将其稀释成10%浓度的冰醋酸溶液后,取碳酸钙51克,氧化镁11克,用与实施例1相同的工艺,制得醋酸钙和醋酸镁的混合溶液,加入6克的甜菊糖苷和9.5克的乳糖,然后用与实施例1相同的工艺得到本发明产品。得到的产品镁与钙离子浓度比为1∶2.4。
实施例3
分别取67毫升和71毫升冰醋酸,将其稀释成10%浓度的冰醋酸溶液,取碳酸钙57克,氧化镁12克,用与实施例1相同的工艺,制得醋酸钙和醋酸镁的混合溶液,加入7克的甜菊糖苷和10.5克的乳糖,然后用与实施例1相同的工艺得到本发明产品。得到的产品镁与钙离子浓度比为1∶4。
Claims (2)
1、一种镁钙离子复合制剂的生产工艺,其特征在于:将冰醋酸稀释成10%的浓度,升温至50℃分别与氧化镁和碳酸钙进行化学反应,生成醋酸镁和醋酸钙溶液,反应温度升至70-75℃后,继续反应25-35分钟;将醋酸镁和醋酸钙溶液进行混合形成混合液,向溶液中加入适量的乳糖和甜菊糖苷,将混合液加温至90℃,恒温45分钟,冷却至常温;过滤混合液;加去离子水至配方量;分装于玻璃瓶中,流通蒸汽100℃,30分钟灭菌;其配方如下:以生产1000毫升镁钙离子复合制剂为准
冰醋酸 124-138毫升
碳酸钙 51-57克
氧化镁 11-12克
乳 糖 9.5-10.5克
甜菊糖苷 6-7克
其余为去离子水。
2、一种用权利要求1镁钙离子复合制剂生产工艺生产的镁钙离子复合制剂,其特征在于:它是醋酸镁、醋酸钙、乳糖和甜菊糖苷的混合溶液,其镁、钙离子浓度比为1∶2-4。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02130855 CN1221268C (zh) | 2002-10-11 | 2002-10-11 | 镁钙离子复合制剂及其生产工艺 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02130855 CN1221268C (zh) | 2002-10-11 | 2002-10-11 | 镁钙离子复合制剂及其生产工艺 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1488359A CN1488359A (zh) | 2004-04-14 |
| CN1221268C true CN1221268C (zh) | 2005-10-05 |
Family
ID=34144651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02130855 Expired - Fee Related CN1221268C (zh) | 2002-10-11 | 2002-10-11 | 镁钙离子复合制剂及其生产工艺 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1221268C (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1732811B (zh) * | 2005-08-10 | 2010-12-22 | 刘志仁 | 生化营养保鲜液 |
| CN101925357B (zh) | 2008-01-28 | 2012-12-12 | 珍明珠集团有限公司 | 含有钙、镁、锌和维生素d3并能预防和改善骨质疏松症的组合物 |
| CN105078950A (zh) * | 2015-08-03 | 2015-11-25 | 兰为民 | 一种含有锌镁钙离子的复合制剂及其制备方法 |
| CN105125579A (zh) * | 2015-09-10 | 2015-12-09 | 重庆布尔动物药业有限公司 | 钙镁维生素注射液 |
| JP6806312B2 (ja) * | 2016-05-27 | 2021-01-06 | エルジー・ケム・リミテッド | 有機発光素子 |
| CN106380388A (zh) * | 2016-08-24 | 2017-02-08 | 华仁药业股份有限公司 | 一种制备药用四水醋酸镁的方法 |
-
2002
- 2002-10-11 CN CN 02130855 patent/CN1221268C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1488359A (zh) | 2004-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109007800A (zh) | 一种用于糖尿病患者的特定全营养配方食品及其制备方法 | |
| Riesenfeld et al. | Glucose homeostasis in the chicken | |
| CN1221268C (zh) | 镁钙离子复合制剂及其生产工艺 | |
| JP2002034592A (ja) | 体内に吸収されやすい蛋白化−亜鉛の製造方法 | |
| CN107373487A (zh) | 一种甘氨酸亚铁冲剂 | |
| CN101513225A (zh) | 一种添加有机锗的复合钙制剂及其制备方法和用途 | |
| CN107417556A (zh) | L‑天门冬氨酸螯合钙及其制备方法 | |
| CN113616667A (zh) | 一种辅助治疗糖尿病的核苷酸组合物及其制备方法和应用 | |
| AU2016311131B2 (en) | Mineral compositions for stimulating the carbohydrate metabolism | |
| CN103735556A (zh) | 一种多维矿物复合泡腾片及制备方法 | |
| Elia | Principles of Clinical Nutrition: Contrasting the practice of nutrition in health and disease | |
| CN107441117A (zh) | 一种多维元素钙制剂及其制备方法 | |
| CN1252231A (zh) | 血红蛋白系列食品及其制造方法 | |
| CN107279620A (zh) | 一种电解质饮料组合物及其制备方法 | |
| CN102948733A (zh) | 一种特殊食用生命营养液的生产方法和配方 | |
| CN107412261A (zh) | 具有修复代谢功能的清糖口服液及其制备方法 | |
| CN100515429C (zh) | 补充钙镁的药品制剂 | |
| CN101117316A (zh) | 一种预防和缓解糖尿病的口服液 | |
| CN110122866A (zh) | 一种慢性肾脏病血管钙化的特殊医学用途食品及制备方法 | |
| CN1225920A (zh) | 氨基酸镁制备的方法及其应用 | |
| US20100016438A1 (en) | Granulated crystal compilation composed of pure organic minerals used in all food applications resulting in energy supplementation, diet and weight regulation, and medicinal effects | |
| CN107595829B (zh) | 一种防治肾性骨营养不良的组合物 | |
| CN113749246B (zh) | 杜仲提取物的制备及其在全营养特殊医学用途配方食品中的应用 | |
| CN1130999A (zh) | Vc补钙饮料及其生产方法 | |
| Yeboah et al. | Metabolic Pathology in Early Postnatal Ontogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |